Company Arch Therapeutics, Inc.

Equities

ARTH

US03939W2089

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Medical Devices & Implants

Market Closed - OTC Markets Other stock markets 08:58:11 13/05/2024 pm IST			5-day change	1st Jan Change
1.04 ^USD	0.00%		+9.47%	-85.64%

09/05	Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
06/05	Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	CI

Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Companyâs flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.

Number of employees: 8

USD in Million	2022	Weight	2023	Weight	Delta
Biotechnology 100.0 %	0	100.0 %	0	100.0 %	+383.80%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	+383.80%

Managers	Title	Age	Since
Terrence Norchi CEO	Chief Executive Officer	59	16/09/16
Michael Abrams DFI	Director of Finance/CFO	55	10/21/10
Shawn Carlson SAM	Sales & Marketing	-	01/21/01

Members of the board	Title	Age	Since
Terrence Norchi CEO	Chief Executive Officer	59	16/09/16
Fish Guy BRD	Director/Board Member	64	31/21/31
Laurence Hicks BRD	Director/Board Member	-	27/21/27
Punit Dhillon BRD	Director/Board Member	44	01/18/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,444,363	3,252,501 ( 73.18 %)	0	73.18 %

Name	Equities	%	Valuation
Michael Bigger 6.326 %	300,000	6.326 %	354 000 $
Brandt Gregory Wilson 6.326 %	300,000	6.326 %	354 000 $
Sixth Borough Capital Fund LP 6.326 %	300,000	6.326 %	354 000 $
Oasis Capital LLC 6.326 %	300,000	6.326 %	354 000 $
Cavalry Fund I Management LLC 6.326 %	300,000	6.326 %	354 000 $
Michael Parker 4.503 %	213,529	4.503 %	251 964 $
Terrence Norchi 1.513 %	71,770	1.513 %	84 689 $
Laurence Hicks 0.2285 %	10,835	0.2285 %	12 785 $
Michael Abrams 0.2170 %	10,292	0.2170 %	12 145 $
Daniel Yrigoyen 0.0158 %	750	0.0158 %	885 $

Arch Therapeutics, Inc.

235 Walnut Street Suite 6

01702, Framingham

http://www.archtherapeutics.com

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Medical Devices & Implants

	1st Jan change	Capi.
ARCH THERAPEUTICS, INC.	-85.64%	4.62M
STRYKER CORPORATION	+8.38%	124B
SMITH & NEPHEW PLC	-6.35%	11.02B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.56%	8.88B
GLAUKOS CORPORATION	+36.32%	5.45B
INSPIRE MEDICAL SYSTEMS, INC.	-21.55%	4.74B
AXONICS, INC.	+8.20%	3.44B
ENOVIS CORPORATION	-7.69%	2.84B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-8.42%	2.15B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-5.20%	2.11B

Medical Devices & Implants